Rezera Inc. postponed its initial public offering on the evening of November 11, one day before its shares were due to begin trading on Nasdaq under the ticker RZRA, citing market conditions. The clinical stage company, known until September as NodThera, had proposed selling about 16.7 million shares at 11 to 13 dollars, worth about 200 million dollars at the midpoint and about a 250 million dollar post money valuation, with Jefferies, TD Cowen and Cantor as joint book runners.
The deal did not lack for signals of support. Smartkarma reported that GSK had indicated nonbinding interest of up to 25 million dollars, and that the pricing already sat at a steep discount to the company’s July financing. Coverage of the book weakened as the week went on, from oversubscribed on Friday to approaching deal size by Monday, and the company chose to wait rather than price into volatility.
The postponement is a financing problem before it is a science verdict. Rezera develops oral inhibitors of NLRP3, a protein central to inflammatory signaling. Its lead candidate, ruvonoflast, is headed for a Phase 3 trial in peripheral artery disease planned for the first half of 2027, with topline results expected in 2028, and the IPO proceeds were earmarked to carry that trial through its readout. The registration statement showed 3.9 million dollars of cash at June 30, 2026, a July financing and term loan that together fund operations only into January 2027, and a going concern qualification that the offering was meant to cure.
No new pricing date has been announced. Alongside the same week’s downsized dental offering, the pulled deal marks the limit of the current IPO comeback: the window is open for some issuers, on some days, and it closed on this one the night before pricing.